（原标题：奕瑞科技现2笔大宗交易 总成交金额2.22亿元） | 成交 | 成交金 | | 相对当 | | | | --- | --- | --- | --- | --- | --- | | 量 | 额 | 成交价 | 日 | | | | （万 | （万 | 格 | 收盘折 溢价 | 买方营业部 | 卖方营业部 | | 股） | 元） | （元） | （%） | | | | 136.18 | 15118.47 | 111.02 | -3.30 | 高盛（中国）证券有限责任公司上海浦东 | 华泰证券股份有限公司成都 | | | | | | 新区世纪大道证券营业部 | 蜀金路证券营业部 | | 64.04 | 7109.78 | 111.02 | -3.30 | 高盛（中国）证券有限责任公司上海浦东 | 华泰证券股份有限公司成都 | | | | | | 新区世纪大道证券营业部 | 蜀金路证券营业部 | 奕瑞科技9月5日大宗交易平台共发生2笔成交，合计成交量200.22万股，成交金额2.22亿元。成交价格均 为111.02元，相对今日收盘价折价3.30%。 注：本文系新闻报道，不构成投资建议，股市有风险，投资需谨慎。 ...

Group 1 - The trading date for the transactions is September 5, 2025, involving the company Yirui Technology (奕瑞科技) with the stock code 688301 [1] - The transaction price for Yirui Technology was 111.02 yuan, with a total transaction amount of 15,118.47 thousand yuan for one of the trades [1] - The trading volume for the same transaction was 136.18, indicating significant trading activity [1] Group 2 - Another transaction on the same date for Yirui Technology had a total transaction amount of 7,109.78 thousand yuan, maintaining the same transaction price of 111.02 yuan [1] - The trading volume for this second transaction was 64.04, reflecting continued interest in the stock [1]

Company Overview - Yirui Technology Co., Ltd. is located at 999 Huanqiao Road, Pudong New District, Shanghai, established on March 7, 2011, and listed on September 18, 2020 [1] - The company's main business involves the research, production, sales, and service of digital X-ray detectors [1] Revenue Composition - The revenue composition of Yirui Technology is as follows: - Detector sales account for 81.21% - Core component sales contribute 7.66% - Solutions/technical services generate 5.89% - Accessory sales make up 4.57% - Rental income is 0.66% [1] Stock Performance - On September 4, Yirui Technology's stock fell by 5.03%, closing at 111.00 CNY per share, with a trading volume of 257 million CNY and a turnover rate of 1.13%, resulting in a total market capitalization of 22.224 billion CNY [1] Fund Holdings - Tianhong Fund has a significant holding in Yirui Technology, with the Tianhong CSI Pharmaceutical 100A fund (001550) holding 183,000 shares, representing 1.09% of the fund's net value, making it the ninth-largest holding [2] - The Tianhong CSI Pharmaceutical 100A fund was established on June 30, 2015, with a latest scale of 755 million CNY [2] Fund Performance - The Tianhong CSI Pharmaceutical 100A fund has achieved a year-to-date return of 18.58%, ranking 2307 out of 4222 in its category, and a one-year return of 32.54%, ranking 2866 out of 3789 [2]

Group 1 - The core point of the article is that Yirui Technology (688301) plans to raise up to 117,362.27 million yuan through a private placement of A-shares to fund the construction of X-ray vacuum devices and comprehensive solutions [1][3] - On September 3, 2025, Yirui Technology's stock closed at 116.88 yuan, with a 3.18% increase and a turnover rate of 1.33% [1] - The company has received approval from the board of directors, shareholders' meeting, Shanghai Stock Exchange, and the China Securities Regulatory Commission for the issuance [1][3] Group 2 - On September 3, the net outflow of main funds was 17.266 million yuan, accounting for 5.6% of the total transaction amount, while retail investors had a net inflow of 44.8991 million yuan, representing 14.57% of the total transaction amount [1][3] - The total investment for the project funded by the raised capital is 156,313.48 million yuan, with a construction period of 36 months [1]

Core Viewpoint - iRay Group is planning to issue shares to specific investors, with the aim of raising funds for the construction of X-ray vacuum devices and comprehensive solutions, totaling an investment of approximately 1.56 billion yuan, of which 1.17 billion yuan will be funded through this issuance [6][7]. Summary by Sections Company Overview - iRay Group is located at 999 Huanqiao Road, Pudong New District, Shanghai, and is involved in the development and manufacturing of X-ray imaging technology [1]. Issuance Details - The company plans to issue no more than 30,032,755 shares, which is capped at 15% of the total share capital as of June 30, 2025 [6]. - The issuance will be priced at 80% of the average trading price over the 20 trading days prior to the pricing date [3][4]. Use of Proceeds - The net proceeds from the issuance will be allocated to the X-ray vacuum devices and comprehensive solutions project, which has a total investment of 1.56 billion yuan [6][7]. - The company may adjust the investment amounts based on project progress and funding needs [6]. Risk Factors - The company highlights several risks, including the potential inability to absorb new production capacity, insufficient technical development for new products, and increased depreciation from new long-term assets [7][10]. - The company also notes the risk of rapid growth in accounts receivable, which could impact cash flow and operational efficiency [9][11]. Financial Health - As of the end of the reporting period, the company's asset-liability ratio was 50.54%, indicating a significant level of debt [11]. - The company has raised funds through convertible bonds and bank loans to finance various projects, which may lead to further increases in debt levels [11]. Market Environment - The company operates in a competitive landscape with significant players such as GE Healthcare, Siemens, and Philips, which are also its clients [15][16]. - Geopolitical tensions and trade frictions may pose risks to the company's international operations and competitiveness [12].

股票简称：奕瑞科技 股票代码：688301 转债简称：奕瑞转债 转债代码：118025 奕瑞电子科技集团股份有限公司 iRay Group （上海市浦东新区环桥路 999 号） 2024 年度向特定对象发行 A 股股票 募集说明书 保荐机构（主承销商） （北京市朝阳区建国门外大街 1 号国贸大厦 2 座 27 层及 28 层） 二〇二五年八月 奕瑞电子科技集团股份有限公司 募集说明书 声 明 本公司及全体董事、监事、高级管理人员承诺募集说明书及其他信息披露资 料不存在任何虚假记载、误导性陈述或重大遗漏，并对其真实性、准确性及完整 性承担连带赔偿责任。 本公司第一大股东、实际控制人承诺本募集说明书及其他信息披露资料不存 在虚假记载、误导性陈述或重大遗漏，并对其真实性、准确性及完整性承担连带 赔偿责任。 公司负责人、主管会计工作负责人及会计机构负责人保证募集说明书中财务 会计资料真实、完整。 中国证券监督管理委员会、上海证券交易所对本次发行所作的任何决定或意 见，均不表明其对申请文件及所披露信息的真实性、准确性、完整性作出保证， 也不表明其对发行人的盈利能力、投资价值或者对投资者的收益作出实质性判断 或保证。任何 ...

| 证券代码：688301 | 证券简称：奕瑞科技 | 公告编号：2025-058 | | --- | --- | --- | | 转债代码：118025 | 转债简称：奕瑞转债 | | 奕瑞电子科技集团股份有限公司 关于参加 2025 年半年度科创板医疗器械及医疗设备 行业集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： （https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络文字互动 投资者可于 2025 年 09 月 10 日（星期三）至 09 月 16 日（星期二）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 （ir@iraygroup.com）进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 奕瑞电子科技集团股份有限公司（以下简称"公司"）于 2025 年 08 月 16 日在上海证券交易所网站（www.sse.com.cn）披露了《2025 年半年度报告》，为 便于广大投资者更全面深入地了解公司的 ...

8月27日，奕瑞科技大宗交易成交10万股，成交额1145.4万元，占当日总成交额的1.98%，成交价114.54元，较市场收盘价114.54元持平。 | 交易日期 | 证券简称 | 证券代码 | 成交价(元) 成交金额(万元) 成交量(*) 买入营业部 | | | | 卖出营业部 | | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-08-27 | 奕瑞科技 | 688301 | 114.54 1145.4 | 10 | 国泰海通证券股份 | 东方证券股份有限 | | | | | | | | 有限公司上海长宁 | 公司芜湖北京中路 | | | | | | | | 区江苏路证券营业 | 证券营业部 | | ...

Group 1: Clinical Trials and Collaborations - The company Henlius (Shanghai Henlius Biopharmaceutical) is collaborating with Carolyn Bertozzi's team to initiate the first human clinical trial next year [2][7] - The therapy being developed is a dual-function sialidase fusion protein therapy aimed at targeting cancer cells [7] Group 2: Scientific Breakthroughs - Carolyn Bertozzi has made significant breakthroughs in bioorthogonal chemistry, which allows for the tracking and modification of specific biomolecules without disrupting natural biological processes [6] - The developed antibody drug targets sialic acid on cancer cells, enhancing the immune system's ability to recognize and eliminate these cells [5][6] Group 3: Impact on Cancer Treatment - The immune therapy developed by Bertozzi's team has the potential to cure certain types of cancer, such as melanoma and lung cancer, which have higher mutation rates and more receptors on their surface [6] - The advancements in cancer immunotherapy are being referred to as a "penicillin moment" for cancer treatment, indicating a significant breakthrough in the field [2]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company reported a revenue of 1.067 billion yuan for H1 2025, a year-on-year increase of 3.94%, and a net profit attributable to shareholders of 335 million yuan, up 8.82% year-on-year [4][5] - In Q2 2025, the company achieved a revenue of 585 million yuan, representing a year-on-year growth of 9.32%, and a net profit of 191 million yuan, which is a 13.86% increase year-on-year [5] - The company is focusing on R&D and expanding into new business areas, with R&D investment reaching 154 million yuan in H1 2025, accounting for 14.46% of revenue [6][9] Summary by Sections Financial Performance - In H1 2025, the company's detector sales generated 866 million yuan, with a year-on-year growth of 2.65% and a gross margin of 60.57% [5] - The overall gross margin for Q2 2025 was 56.31%, with a sales expense ratio of 3.95% and a management expense ratio of 6.05% [5] R&D and Innovation - The company has increased its R&D efforts, registering 70 new IPs, including 32 invention patents [6] - The company is advancing the development of various new detectors and has successfully launched several micro-focus X-ray sources, breaking the import monopoly in this field [6][8] Market Expansion - The company is actively expanding its market presence by providing a range of core components and integrated solutions, with core component sales reaching 82 million yuan, up 16.90% year-on-year [7] - The company is also entering the silicon-based OLED backplane market, with an investment of up to 1.8 billion yuan to increase production capacity [8] Future Projections - Revenue projections for 2025-2027 are 2.266 billion yuan, 3.100 billion yuan, and 4.133 billion yuan, with year-on-year growth rates of 23.7%, 36.8%, and 33.3% respectively [9] - Expected net profits for the same period are 647 million yuan, 832 million yuan, and 1.101 billion yuan, with corresponding year-on-year growth rates of 39.1%, 28.6%, and 32.3% [9]